August 18th 2025
Catch up on recent advancements in retina care, including new therapies for age-related macular degeneration and macular telangiectasia, enhancing patient outcomes.
Perspectives on intravenous bevacizumab repackaged for intravitreal use
June 15th 2022Although off-label repackaged bevacizumab syringes appear to satisfy an urgent clinical and financial need for patients with a variety of retinal disorders, they are known to be associated with considerable public health concerns due to the risks posed to patients from compounding pharmacies’ lack of compliance with a variety of FDA requirements.
Key discovery: Humanin G reduces protein levels of inflammation markers associated with AMD
June 8th 2022According to the study by a team of researchers from the University of California Irvine and University of Southern California, treatment with Humanin G reduced protein levels of inflammation markers that become elevated in age-related macular degeneration.
New drug application filed for pegcetacoplan for the treatment of geographic atrophy
June 1st 2022The company noted that pegcetacoplan, designed to regulate excessive activation of the complement cascade, part of the body’s immune system, which can lead to the onset and progression of many serious diseases, was granted Fast Track designation by the FDA for the treatment of geographic atrophy.
Geographic atrophy survey reveals heavy emotional burden, decreased independence for patients
April 26th 2022Apellis Pharmaceuticals releases results of their Geographic Atrophy Insights Survey (GAINS), revealing a large emotional toll and significant decrease in independence for patients with geographic atrophy.
Outcomes of anti-VEGF therapy for retinal diseases altered by COVID-19 lockdown
April 8th 2022Investigators found that patients with neovascular age-related macular degeneration in all countries included in the study lost vision as a result of the lockdown and reduced number of treatments during the COVID-19 pandemic.
Outlook Therapeutics submits BLA for ophthalmic bevacizumab ONS-5010 as treatment for wet AMD
March 31st 2022If the Biologics License Application is approved by the FDA, the company could receive 12 years of marketing exclusivity for an FDA-approved alternative for the most frequently used anti-VEGF treatment in wet AMD patients in the United States.
LIGHTSITE III clinical trial update: LumiThera shares data for dry AMD therapy
March 27th 2022The company notes that its clinical trial of the light delivery system meets the primary efficacy endpoint and can offer hope to patients with dry AMD who are experiencing vision loss and currently have limited treatment options.
Drug designed to decrease alcohol dependence may save vision for patients with RP, AMD
March 26th 2022According to a team of investigators at University of California, Berkeley, tests of the drug Antabuse could prove the role of hyperactive retinal cells in blindness, potentially leading to better therapies.
Apellis unveils 18-month results from phase 3 OAKS and DERBY studies
March 16th 2022According to the company, pegcetacoplan demonstrated continuous and clinically meaningful effects at month 18 in the studies, which also found that treatment effects in DERBY were comparable to OAKS during months 6 to 18. The combined 18-month data show the potential for improving treatment effects over time.